Where does Trevi Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$35.61M-7.2%	$33.48M-15.0%	$36.61M+0.1%	$37.75M+19.2%	$38.38M+39.6%
General and administrative	$17.16M+35.1%	$15.85M+30.5%	$14.74M+26.5%	$13.77M+19.7%	$12.71M+17.9%
Compensation and benefits	$6.17M+51.4%	$5.19M+44.5%	$4.75M+48.2%	$4.33M+48.6%	$4.07M+75.8%
Depreciation and amortization	$141K-5.4%	$144K-2.0%	$151K+4.9%	$149K+4.2%	$149K+7.2%
Other operating expenses	9,187,800,000%+150,800,000%	8,843,600,000%-237,000,000%	9,063,200,000%+1,742,700,000%	9,080,300,000%+2,264,000,000%	9,037,000,000%+2,711,400,000%
Total operating expenses	$52.77M+3.3%	$49.33M-4.3%	$51.35M+6.5%	$51.52M+19.3%	$51.09M+33.5%
Operating income	-$52.77M-3.3%	-$49.33M+4.3%	-$51.35M-6.5%	-$51.52M-19.3%	-$51.09M-33.5%
Interest income	$7.11M+90.6%	$6.54M+81.5%	$5.48M+40.6%	$4.2M-1.2%	$3.73M—
Other income (expense), net	$7.09M+91.2%	$6.51M+81.6%	$5.46M+41.2%	$4.18M-4.8%	$3.71M-20.6%
Net investment gains (losses)	$0—	$0—	$0—	$0—	$0—
Income before income taxes	-$45.68M+3.6%	-$42.82M+10.7%	-$45.89M-3.5%	-$47.35M-22.1%	-$47.38M-41.0%
Income tax expense	-$72K—	-$63K—	——	——	——
Net income	-$45.61M+3.7%	-$42.76M+10.8%	-$45.86M-3.5%	-$47.3M-22.0%	-$47.35M-41.1%
Diluted earnings per share	-$0.32+28.9%	-$0.32+31.9%	-$0.37+15.9%	-$0.42-7.7%	-$0.45-32.4%
Basic earnings per share	-$0.32+28.9%	-$0.32+31.9%	-$0.37+15.9%	-$0.42-7.7%	-$0.45-32.4%
Weighted-average shares, diluted	555.8M+31.7%	527.8M+30.7%	495M+23.5%	451.2M+13.1%	421.9M+6.4%
Weighted-average shares, basic	555.8M+31.7%	527.8M+30.7%	495M+23.5%	451.2M+13.1%	421.9M+6.4%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.67M+21.2%	$1.64M+19.8%	$1.37M-3.4%	$1.43M-7.3%	$1.38M-24.7%
Share-based compensation expense related to employee stock plans	$6.17M+51.4%	$5.19M+44.5%	$4.75M+48.2%	$4.33M+48.6%	$4.07M+70.2%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	$38K-99.3%	-$15.18M-993%	$40.82M+512%	$104.1M+13,293%	$5.56M+158%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$45.87M+2.8%	-$42.67M+10.8%	-$45.97M-4.6%	-$47.19M-22.2%	-$47.21M-40.7%
Current Federal, State and Local, Tax Expense (Benefit)	——	-$64K-113%	-$55.5K-82.0%	-$47K-51.6%	-$38.5K-22.2%
Current State And Local Tax Expense Benefit	——	-$64K-113%	-$55.5K-82.0%	-$47K-51.6%	-$38.5K-22.2%
Total net securities (losses)	$0—	$0—	$0—	$0—	$0—
Dividends, Common Stock, Cash	$0—	$0—	$0—	$0—	$0—
Effective tax rates	——	$00.0%	$00.0%	$00.0%	$00.0%
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Other	——	$0—	$0—	$0—	$0—
Share-based compensation	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Finance Lease Principal Payments	——	$11K-91.3%	$42K-67.2%	$74K-42.2%	$106K-17.2%
Income Tax Credits Exchanged For Cash	——	$33K+3.1%	$32.75K-13.2%	$32.5K-25.3%	$32.25K-34.5%
State taxes	——	-$33K-3.1%	-$32.75K—	-$32.5K—	-$32.25K—
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$8.96M-13.5%	$9.31M—	$9.66M—	$10.01M—
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$8.99M+10.7%	-$9.26M—	-$9.53M—	-$9.8M—
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$14K+193%	$6.75K—	-$500—	-$7.75K—
Share-based compensation	——	$1.2M+34.5%	$1.13M—	$1.05M—	$972.25K—
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	-$69K+15.9%	-$72.25K—	-$75.5K—	-$78.75K—
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$1.18M+5.8%	$1.16M—	$1.15M—	$1.13M—
Income Taxes Paid, Net	——	-$33K-3.1%	-$32.75K—	-$32.5K—	-$32.25K—
Accounts payable	——	——	——	——	-$682K—
Accrued liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$1.64M+160%	$784K+153%	-$1.55M-202%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$112.53M+60.3%	$121.01M+96.8%	$172.2M+1,628%	$175.55M—	$70.22M—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$67.19M—	-$94.11M—	-$87.37M—	-$28.77M—	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$45.3M-9.8%	-$42.09M-10.0%	-$44.01M-25.5%	-$42.68M-30.2%	-$41.27M-21.4%
Number of operating segments	——	——	——	——	——
Number of reportable segments	——	——	——	——	——
Offering Costs Included In Accrued Expenses	——	——	——	——	——
Operating lease right-of-use assets amortization expense	$430K-4.9%	$437K-5.0%	$528K+38.9%	$449K-4.5%	$452K—
Unrealized gains (losses) on available-for-sale securities	-$263K—	$87K—	——	——	——
Other income, net (Note 6)	-$20K—	-$30K—	——	——	——
Payments Of Stock Issuance Costs	——	$809K—	——	——	——
Payments to Acquire Marketable Securities	$151.6M+58.3%	$170.66M+73.3%	$161.46M+198%	$102.9M—	$95.75M—
Payments to Acquire Property, Plant, and Equipment	——	——	——	——	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$84.52M+16.8%	$76.57M-0.5%	$74.11M+6.7%	$74.14M+11.1%	$72.39M-1.7%
Proceeds From Offering Net Of Commissions	——	$108.15M+130%	$92.87M—	$77.58M—	$62.29M—
Cash received from option exercises	$1.58M+42.9%	$2.08M+428%	$1.87M+389%	$907K+309%	$1.11M+6,825%
Proceeds From Warrant Exercises	——	——	——	——	——
Stock-based compensation	$6.17M+51.4%	$5.19M+44.5%	$4.75M+48.2%	$4.33M+48.6%	$4.07M+75.8%
Weighted-average grant date fair value of stock options (in dollars per share)	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	——	——	——	——	——
Risk-free interest rates, high end of range (as a percent)	——	——	——	——	——
Risk-free interest rates, low end of range (as a percent)	——	——	——	——	——
Volatilities, high end of range (as a percent)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	——	——	——	——	——
Volatilities, low end of range (as a percent)	——	——	——	——	——
Intrinsic value of stock options exercised	——	$4.34B+1,421,867%	$3.25B+1,195,792%	$2.17B+907,286%	$1.08B+526,346%
Options canceled (in dollars per share)	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Options forfeited/expired (in dollars per share)	——	——	——	——	——
Exercised (in shares)	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1	——	$4.5M+87.5%	$3.98M+78.7%	$3.45M+68.3%	$2.93M+56.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	——	$107.42M+130%	$119.09M—	$130.78M—	$35.08M—
Stock Issued During Period, Value, Stock Options Exercised	$1.58M+43.0%	$2.08M+429%	$1.87M+390%	$906K+308%	$1.11M+7,280%
Stock Issued During Period Value Stock Warrant Exercise	——	——	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	$11.2M-13.2%	$11.63M-1.3%	$12.05M+13.1%	$12.48M+31.0%
Write Off Of Deferred Offering Costs	——	$26K—	——	——	——
EBIT	-$52.77M-3.3%	-$49.33M+4.3%	-$51.35M-6.5%	-$51.52M-19.3%	-$51.09M-33.5%
EBITDA	-$52.63M-3.3%	-$49.18M+4.3%	-$51.2M-6.5%	-$51.37M-19.4%	-$50.94M-33.6%
EBITDA	-$52.63M-3.3%	-$49.18M+4.3%	-$51.2M-6.5%	-$51.37M-19.4%	-$50.94M-33.6%
EBIT	-$52.77M-3.3%	-$49.33M+4.3%	-$51.35M-6.5%	-$51.52M-19.3%	-$51.09M-33.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Trevi Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.